Silence Therapeutics (SLN) FCF Margin (2024 - 2026)
Silence Therapeutics (SLN) posted FCF Margin of 3697.39% for Q1 2026, up 92.74% sequentially from 50929.41% in Q4 2025, and up 497373.0% YoY from N/an in Q1 2025.
Silence Therapeutics (SLN) FCF Margin (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported FCF Margin for 3 years, with the latest figure at 3697.39% in Q1 2026.
- Quarterly FCF Margin rose 497373.0% year-over-year to 3697.39% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7824.2% (down 756822.0% YoY) and the FY2025 annual result came in at 11154.74%, down 1099789.0% from the prior year.
- FCF Margin improved to 3697.39% in Q1 2026 per SLN's latest filing, from 50929.41% in the prior quarter.
- Over five years, FCF Margin peaked at 58.24% in Q1 2024 and troughed at 50929.41% in Q4 2025.
- A 3-year average of 9158.87% and a median of 3697.39% in 2026 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2025 and 2026: FCF Margin slumped 5081777 bps in 2025, then surged 497373 bps in 2026.
- Over 3 years, FCF Margin stood at 111.64% in 2024, then sank by 45520 bps to 50929.41% in 2025, then surged by 93 bps to 3697.39% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 3697.39%, 50929.41%, and 6888.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,697.39% |
| Dec 31, 2025 | -50,929.41% |
| Sep 30, 2025 | -6,888.68% |
| Jun 30, 2025 | -9,720.09% |
| Mar 31, 2025 | -8,671.13% |
| Dec 31, 2024 | -111.64% |
| Sep 30, 2024 | -1,666.49% |
| Jun 30, 2024 | -686.75% |
| Mar 31, 2024 | -58.24% |